Trials / Not Yet Recruiting
Not Yet RecruitingNCT07243366
Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis
Exploratory Clinical Trial of Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-center, prospective, nonrandom, single-arm trial.
Detailed description
This study is a single-center, prospective, nonrandom, single-arm trial. To evaluate the clinical safety and efficacy of allogeneic CD19-CAR-NK Cells in patients with refractory myasthenia gravis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CD19-CAR-NK Cells Injection | Allogeneic CD19-CAR-NK cells will be administered intravenously at a fixed dose, once every two weeks for a total treatment duration of 24 weeks. |
Timeline
- Start date
- 2025-11-25
- Primary completion
- 2027-06-30
- Completion
- 2027-11-30
- First posted
- 2025-11-21
- Last updated
- 2025-11-21
Source: ClinicalTrials.gov record NCT07243366. Inclusion in this directory is not an endorsement.